Sanofi-Aventis SA, of Paris, will retain the existing rights for the products in countries outside the U.S. Terms of the agreement were not disclosed

Among the first companies (or precursors of today's companies, the case of Sanofi) to enter the continent were Abbott (South Africa, 1930s), Sanofi-Aventis (Morocco, 1953), Novartis (Egypt, 1962), Pfizer (Morocco, 1963) and GlaxoSmithKline (GSK, Nigeria, 1971

Among the first companies (or precursors of today's companies, the case of Sanofi) to enter the continent were Abbott (South Africa, 1930s), Sanofi-Aventis (Morocco, 1953), Novartis (Egypt, 1962), Pfizer (Morocco, 1963) and GlaxoSmithKline (GSK, Nigeria, 1971

Among the first companies (or precursors of today's companies, the case of Sanofi) to enter the continent were Abbott (South Africa, 1930s), Sanofi-Aventis (Morocco, 1953), Novartis (Egypt, 1962), Pfizer (Morocco, 1963) and GlaxoSmithKline (GSK, Nigeria, 1971

Regulus, which was born out of technologies from Isis and Alnylam, has established packs with GlaxoSmithKline plc, AstraZeneca plc, Sanofi-Aventis Group SA and Biogen Idec. (SeeBioWorld Today, April 18, 2008, June 23, 2010, and Aug. 22, 2012.) The biotech went public in October, despite not having any drugs in the clinic

Biotech Products Approved in 2013 | Biotech Products Approved 1982-2012 BIOTECH PRODUCTS 2013 Company Product Marketer Indication (U.S. Approval Date; Month/Day) Arbor Pharmaceuticals Inc. Nymalize Arbor Pharmaceuticals Inc. Subarachnoid hemorrhage (5/15) Algeta ASA Xofigo Bayer AG Castration-resistant prostate cancer (5/16) Genentech Inc. Tarceva Astellas Pharma Inc. Metastatic non-small-cell lung cancer (5/16) Theravance Inc. Breo Ellipta

Its most successful resident was antibiotic developer Novexel SA, a spinout of Sanofi Aventis Group (now Paris-based Sanofi SA), which London-based AstraZeneca plc acquired in 2009 for $505 million

OncoGenex, of Bothell, Wash., recently disclosed the start of AFFINITY, a Phase III study that pairs custirsen, which is based on Carlsbad, Calif.-based Isis Pharmaceuticals Inc.'s second-generation antisense technology, with Jevtana (cabazitaxel), Paris-based Sanofi-Aventis SA's second-line therapy for prostate cancer

Beyond T-DM1, ImmunoGen has nine additional ADC compounds in the clinic covering a broad range of solid and liquid tumor types, including three programs wholly owned by the company and other partnered programs with Eli Lilly & Co., Novartis AG, Amgen Inc., Bayer HealthCare, Sanofi Aventis Group and Biotest AG

And the story of its development, senior author George Kunos told BioWorld Today, is tied to the rise and fall of Acomplia (rimonabant, Sanofi-Aventis Group SA

And the story of its development, senior author George Kunos told BioWorld Today, is tied to the rise and fall of Acomplia (rimonabant, Sanofi-Aventis Group SA

The company conducted a major pruning of its pipeline last year to focus on cabo's development, and nearly a dozen compounds in its portfolio have been out-licensed to partners, including GlaxoSmithKline plc, of London, Sanofi-Aventis SA, of Paris, and Bristol-Myers Squibb Co., of New York. (See BioWorld Today, Dec. 17, 2007, Dec. 15, 2008, May 29, 2009, Oct. 12, 2010, and Dec. 27, 2011.) On Wednesday, shares of Exelixis (NASDAQ:EXEL) lost 3 cents during a broad market swoon, closing at $4.59

Several therapies in late-stage development are being lined up to join recently approved therapies such as Dendreon Corp.'s autologous cell therapy Provenge (sipuleucel-T), Sanofi Aventis SA's taxane Jevtana (cabazitaxel) and Johnson & Johnson's androgen biosynthesis inhibitor Zytiga (abiraterone acetate

Several therapies in late-stage development are being lined up to join recently approved therapies such as Dendreon Corp.'s autologous cell therapy Provenge (sipuleucel-T), Sanofi Aventis SA's taxane Jevtana (cabazitaxel) and Johnson & Johnson's androgen biosynthesis inhibitor Zytiga (abiraterone acetate

Several therapies in late-stage development are being lined up to join recently approved therapies such as Dendreon Corp.'s autologous cell therapy Provenge (sipuleucel-T), Sanofi Aventis SA's taxane Jevtana (cabazitaxel) and Johnson & Johnson's androgen biosynthesis inhibitor Zytiga (abiraterone acetate

Sanofi-Aventis; Paris) Valeant Pharmaceuticals International Inc. (Mississauga, Ont.) 7/11/11 12/14/11 $425 Valeant paid $425M for the Sanofi unit Excaliard Pharmaceuticals (San Diego) Pfizer Inc. (New York) 11/23/11 12/5/11 ND Pfizer acquired Excaliard with an undisclosed up-front payment and potential milestones, a portion of which, up to $14M, will go to Isis Pharmaceuticals Inc

Enterome's six-member management team includes scientists specializing in biomarker development and former founders and executives of ophthalmology drug developer Fovea Pharmaceuticals SA, acquired in 2009 by Sanofi Aventis Group, of Paris, in a $538 million deal. (See BioWorld Today, Oct. 2, 2009.) Belichard was Fovea's co-founder and chief operating officer

by Sanofi-Aventis SA, of Paris, and the last-minute nab of Advanced BioHealing Inc. (ADH), by Shire plc, of Dublin, Ireland. (See BioWorld Today, Feb. 17, 2011, and May 19, 2011.) "When you're a pharma looking at this field, one of the most fundamental decisions to make is whether to build capabilities, buy capabilities, invest externally, partner, wait or watch and see," said Jay Siegel, chief biotechnology officer and head of pharmaceutical global regulatory affairs for New Brunswick, N.J

Sanofi-Aventis SA (Paris) $161 Exelixis terminated the preclinical programs that were part of a 2009 P13K collaboration Exelixis received $140M up front in the May 2009 deal, which provided for another $21M in R&D funding over three years (12/27) Idera Pharmaceuticals Inc. (Cambridge, Mass.) Merck KGaA (Darmstadt, Germany) ND Merck returned global rights to IMO-2055, a TLR9 agonist, as a cancer therapy The rights were returned due to the termination of their oncology collaboration (12/1) Napo